Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

New labeling is being eyed regarding increased risks for blood clots for the contraceptive patch and combined oral contraceptives (COCs) containing the progestin drospirenone (DRSP) following recommendations from joint votes from two Food and Drug Administration (FDA) committees.

Set to change: Patch, drospirenone OC labels